Professor of Medical Oncology, Loyola University-Stritch School of Medicine
Hematology
Dr. Kathy S. Albain, MD
|
|
Give Review
Doctor Kathy S. Albain, MD practices Hematology. She graduated from University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago is ranked 49/85 in Research/PrimaryCare. She received awards:"West Suburban Living Magazine", "America's Top Doctors", "Chicago Magazine: Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Women's Health", "Redbook Magazine: Top Breast Cancer Doctors", "Top MD" and "Super Doctor". Doctor Kathy S. Albain, MD is a published doctor and has 60 publications published. The lastest was: 'Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
- Goserelin for ovarian protection during breast-Cancer adjuvant chemotherapy.
- The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer.
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast Cancer.
- SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer.
- Supportive care after curative treatment for breast Cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initia...
- Higher capecitabine AUC in elderly patients with advanced colorectal Cancer (SWOGS0030).
- Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast Cancer.
- Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy.
- Supplement use during an intergroup clinical trial for breast Cancer (S0221).
- Patient income level and Cancer clinical trial participation.
- Impact of Multigene Assays in Early Stage Breast Cancer.
- Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results fr...
- SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast Cancer.
- Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast Cancer treatment trial (S0221).
- Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung Cancer.
- Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast Cancer.
- Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast Cancer.
- Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung Cancer: Southw...
- Reply to P. Brauchli et al.
- A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenoCarcinoma of the lung.
- Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast Cancer treatment selection.
- Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followe...
- Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast Cancer in SWOG-8897.
- Assessing breast Cancer risk and providing treatment recommendations: immediate impact of an educational session.
- Outcome of patients with early-stage breast Cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
- Nitric oxide synthase variants and disease-free survival among treated and untreated breast Cancer patients in a Southwest Oncology Group clinical trial.
- Racial disparities in Cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
- Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast Cancer.
- Treatment quality and outcomes of African American versus white breast Cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.
- Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings.
- Prevalence of secondary causes of bone loss among breast Cancer patients with osteopenia and osteoporosis.
- Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast Cancer and prior anthracycline treatment.
- Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung Cancer: ...
- Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast Cancer: Southwest Oncology Gr...
- Late cardiac effects of adjuvant chemotherapy in breast Cancer survivors treated on Southwest Oncology Group protocol s8897.
- Impact of a peer-delivered telephone intervention for women experiencing a breast Cancer recurrence.
- p27(Kip1) and cyclin E expression and breast Cancer survival after treatment with adjuvant chemotherapy.
- New developments in the epidemiology of Cancer prognosis: traditional and molecular predictors of treatment response and survival.
- Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung Cancer: a phase II Southwest Oncology G...
- Clinical factors used to support prophylactic mastectomy for a male BRCA2 mutation carrier.
- PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung Cancer and perform...
- Acute Lung injury associated with vinorelbine.
- Correlation of nipple aspiration and Ductal lavage cytology with histopathologic findings for patients before scheduled breast biopsy examination.
- Impact of the year 2000 Medicare policy change on older patient enrollment to Cancer clinical trials.
- Reducing the global breast Cancer burden: the importance of patterns of care research.
- Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung Cancer: rationale for consolidation docetaxel therapy.
- Current standards and ongoing controversies in the management of locally advanced non-small cell lung Cancer.
- Multimodality therapy for stage III non-small-cell lung Cancer.
- Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung Cancer: a retrospective review by the Southwest Oncology Group.
- Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast Cancer.
- Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung Cancer : a realistic goal?
- Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast Cancer: a tale of three trials.
- The potential role of surgery after inDuction treatment.
- Gemcitabine in patients with non-small-cell lung Cancer previously treated with platinum-based chemotherapy: a phase II California Cancer consortium trial.
- Breast Cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung Cancer: a randomized trial.
- Quantification of chemotherapeutic target gene mRNA expression in human breast Cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantifi...
- Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung Cancer: a Southwest Oncology Group phase II study, SWOG 9019.
Schools
University Of Michigan Medical School
University Ill Med Center
University Chicago Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- West Suburban Living Magazine
- America's Top Doctors
- Chicago Magazine: Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Women's Health
- Redbook Magazine: Top Breast Cancer Doctors
- Top MD
- Super Doctor
Education
-
University of Chicago -
University of Illinois College of Medicine at Chicago -
University of Michigan Medical School
Hospital
-
Sarah Bush Lincoln Health Center
Drug Facts
| NPI NUMBER | 1679550842 | |
| NPPES Provider LastName | ALBAIN | |
| NPPES Provider FirstName | KATHY | |
| NPPES Provider ZIPCode | 60153 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 616.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 94.0 | |
| Percent Opioid Claims | 15.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679550842 |
| Last Name Of The Provider | ALBAIN |
| First Name Of The Provider | KATHY |
| View All |
Similar Doctors
|
|
Dr. Janelle M. Meyer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricia A. Robinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen Gaynor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth C. Micetich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepak Malhotra, MD |
|
|
Dr. Joseph I. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aileen Go, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sucha Nand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Malini M. Patel, MD |
|
|
Dr. Kathrine A. Wentland, MD |